Patent intelligence · US
US 10881644
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
Patent details — US 10881644
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 5, 2021
- Expiration
- Dec 31, 2040
- Applicant
- Lutonix, Inc.
- Claims
- 11
- CPC classes
- A61K, A61K31/337, A61K31/436, A61K9/0019
Quick answer
US 10881644 (Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs) is held by Lutonix, Inc.. Status: granted. Granted Jan 5, 2021. Expires Dec 31, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Lutonix, Inc.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K31/337, A61K31/436, A61K9/0019, A61K9/0073
More from Lutonix, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12383733
Iontophoresis-based patch type medicine absorption device
granted -
US 12365879
Synthetic chimeric poxviruses
granted -
US 12304901
Selective ligands for tau aggregates
granted -
US 12156897
Magnesium-containing oxytocin formulations and methods of use
granted -
US 12156864
Analogs of cyclobenzaprine and amitryptilene
granted -
US 12097183
Pharmaceutical composition for treating migraine
granted -
US 12090139
Formulations comprising triptan compounds
granted -
US 11998516
Methods and compositions for treating depression using cyclobenzaprine
granted
Frequently asked questions
What is US patent 10881644?
US 10881644 (Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs) is held by Lutonix, Inc.. Status: granted. Granted Jan 5, 2021. Expires Dec 31, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10881644?
Lutonix, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 86 pharmaceutical patents for this assignee.
When does US 10881644 expire?
Our index shows an expiration date of Dec 31, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.